# Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rituximab-treatment-for-posttransplant-lymphoproliferative-disorder-ptld-induces/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kandai Nozu,Kazumoto Iijima,Masato Fujisawa,Atsuko Nakagawa,Norishige Yoshikawa,Masafumi Matsuo |
| Citations | 140 |
| DOI | 10.1007/s00467-005-2013-7 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1966488593 |
| PMID | 16133051 |
| Type | article |
| Year | 2005 |

## Paper authors

- [Kandai Nozu](https://scholariq.org/researchers/kandai-nozu/)
- [Kazumoto Iijima](https://scholariq.org/researchers/kazumoto-iijima/)

## Paper journal

- [Pediatric Nephrology](https://scholariq.org/journals/pediatric-nephrology/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.